Modulation of Treatment Effect on Disability by Disease Activity in Progressive Multiple Sclerosis: An Individual Patient Data Meta-Analysis.
作者信息
Montobbio Noemi, Bovis Francesca, Arnold Douglas L, Sormani Maria Pia
机构信息
Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
Research, NeuroRx, Montréal, Quebec, Canada.
出版信息
JAMA Neurol. 2025 Jul 28. doi: 10.1001/jamaneurol.2025.2565.
Abstract
摘要
相似文献
1
Modulation of Treatment Effect on Disability by Disease Activity in Progressive Multiple Sclerosis: An Individual Patient Data Meta-Analysis.疾病活动度对进展性多发性硬化症残疾治疗效果的调节作用：一项个体患者数据荟萃分析
JAMA Neurol. 2025 Jul 28. doi: 10.1001/jamaneurol.2025.2565.
2
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.用于多发性硬化症的免疫调节剂和免疫抑制剂：一项网状Meta分析
Cochrane Database Syst Rev. 2013 Jun 6;2013(6):CD008933. doi: 10.1002/14651858.CD008933.pub2.
3
Azathioprine for people with multiple sclerosis.硫唑嘌呤用于多发性硬化症患者。
Cochrane Database Syst Rev. 2024 Dec 9;12(12):CD015005. doi: 10.1002/14651858.CD015005.pub2.
4
Teriflunomide for multiple sclerosis.特立氟胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2016 Mar 22;3(3):CD009882. doi: 10.1002/14651858.CD009882.pub3.
5
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.用于复发缓解型多发性硬化症的免疫调节剂和免疫抑制剂：一项网状荟萃分析。
Cochrane Database Syst Rev. 2015 Sep 18;2015(9):CD011381. doi: 10.1002/14651858.CD011381.pub2.
6
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.免疫调节剂和免疫抑制剂治疗复发缓解型多发性硬化症的网状 Meta 分析。
Cochrane Database Syst Rev. 2024 Jan 4;1(1):CD011381. doi: 10.1002/14651858.CD011381.pub3.
7
Rituximab for people with multiple sclerosis.利妥昔单抗治疗多发性硬化症。
Cochrane Database Syst Rev. 2021 Nov 8;11(11):CD013874. doi: 10.1002/14651858.CD013874.pub2.
8
Natalizumab for relapsing remitting multiple sclerosis.那他珠单抗用于复发缓解型多发性硬化症。
Cochrane Database Syst Rev. 2011 Oct 5(10):CD007621. doi: 10.1002/14651858.CD007621.pub2.
9
WITHDRAWN: Interventions for fatigue and weight loss in adults with advanced progressive illness.撤回：针对晚期进行性疾病成人患者疲劳和体重减轻的干预措施。
Cochrane Database Syst Rev. 2017 Apr 7;4(4):CD008427. doi: 10.1002/14651858.CD008427.pub3.
10
Interventions for fatigue and weight loss in adults with advanced progressive illness.针对患有晚期进行性疾病的成年人疲劳和体重减轻的干预措施。
Cochrane Database Syst Rev. 2012 Jan 18;1:CD008427. doi: 10.1002/14651858.CD008427.pub2.
本文引用的文献
1
Is the effect of drugs in progressive MS only due to an effect on inflammation? A subgroup meta-analysis of randomised trials.进展型多发性硬化症中药物的疗效是否仅归因于对炎症的作用？一项随机试验的亚组荟萃分析。
Mult Scler. 2022 Oct;28(11):1744-1751. doi: 10.1177/13524585221094944. Epub 2022 May 17.
2
Applied mediation analyses: a review and tutorial.应用中介分析：综述与教程
Epidemiol Health. 2017 Aug 6;39:e2017035. doi: 10.4178/epih.e2017035. eCollection 2017.
3
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.利妥昔单抗治疗原发性进行性多发性硬化症患者：一项随机双盲安慰剂对照多中心试验的结果
Ann Neurol. 2009 Oct;66(4):460-71. doi: 10.1002/ana.21867.
Zotero 插件